本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于2025年10 月20日召开第四届董事会第十一次会议，审议通过了《关于变更注册 资本暨修订<公司章程>的议案》，拟对《英科医疗科技股份有限公司 章程》（以下简称"《公司章程》"）的相关条款进行修订。具体情 况如下： 一、公司注册资本变更情况 证券代码：300677 证券简称：英科医疗 公告编号：2025-142 英科医疗科技股份有限公司 关于变更注册资本暨修订《公司章程》的公告 | | 原章程内容 | | 修订后章程内容 | | --- | --- | --- | --- | | | 第六条 | 公司注册资本为人民 | 第六条 公司注册资本为人民 | | | 币 64,170.0369万元。 | | 币65,438.3263万元。 | | | 第二十一条 | 公司股份总数为 | 第二十一条 公司股份总数为 | | 64,170.0369万股，均为普通股。 | | | 65,438.3263万股，均为普通股。 | 本次《公司章程》相关条款作如下修订： 除上述修订内容和条款外， ...

英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 20 日召 开第四届董事会第十一次会议，审议通过了《关于召开公司 2025 年第六次临 时股东会的议案》，公司决定于 2025 年 11 月 5 日（星期三）14:00 召开公司 2025 年第六次临时股东会。 证券代码：300677 证券简称：英科医疗 公告编号：2025-143 英科医疗科技股份有限公司 关于召开 2025 年第六次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 现将会议相关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第六次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件 及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 05 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-138 英科医疗科技股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 英科医疗科技股份有限公司（以下简称"公司"）第四届董事会 第十一次会议于 2025 年 10 月 20 日在公司会议室以现场结合通讯方 式召开，会议通知已于 2025 年 10 月 17 日以专人送达、电子邮件、 传真或即时通讯工具等形式向全体董事发出。会议由公司董事长刘方 毅先生召集和主持，本次会议应出席董事 9 名，实际出席会议董事 9 名，公司高级管理人员列席了本次会议。会议的召集和召开符合《中 华人民共和国公司法》《英科医疗科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定。 1、审议通过《关于参与投资Warburg Pincus Global Growth 15, L.P.暨关联交易的议案》 为进一步优化投资结构，提升全球战略布局，公司之全资子公司 英科医疗国际（香港）有限公司（以下简称"英科医疗国际"）拟与 Warburg Pincus Gl ...

人民财讯10月20日电，英科医疗（300677）10月20日公告，公司全资子公司英科医疗国际拟与华平投资 签署认购协议，以自有资金参与投资Warburg Pincus Global Growth15,L.P.(简称"基金")。基金的目标募 集规模为170亿美元，其中，英科医疗国际将作为该合伙企业的有限合伙人(LP)认缴出资7000万美元。 ...

Core Viewpoint - The company plans to invest $70 million in the Warburg Pincus Global Growth 15, L.P. partnership, which aims to raise a total of $17 billion [1] Group 1: Investment Details - The investment will be made by the company's wholly-owned subsidiary, Yingke Medical International (Hong Kong) Limited [1] - The transaction is classified as a related party transaction but does not exceed 5% of the company's latest audited net assets, thus not requiring shareholder approval [1] Group 2: Strategic Objectives - The investment aims to optimize the company's investment structure and enhance its global strategic layout [1] - The company seeks to leverage a specialized investment management team to improve its revenue levels and long-term strategic development [1]

Group 1 - In October 17, 2023, Yingke Medical's stock price dropped by 5.05%, closing at 43.20 CNY per share, with a trading volume of 1.434 billion CNY and a turnover rate of 6.69%, resulting in a total market capitalization of 28.287 billion CNY [1] - Yingke Medical Technology Co., Ltd. was established on July 20, 2009, and listed on July 21, 2017. The company operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - Among the top ten circulating shareholders of Yingke Medical, a fund under E Fund Management holds a significant position. The E Fund ChiNext ETF (159915) reduced its holdings by 272,900 shares in the second quarter, now holding 10.6244 million shares, which accounts for 2.26% of the circulating shares. The estimated floating loss today is approximately 24.4362 million CNY [2] - The E Fund ChiNext ETF (159915) was established on September 20, 2011, with a current scale of 85.537 billion CNY. Year-to-date, it has achieved a return of 43.58%, ranking 745 out of 4,218 in its category; over the past year, it has returned 50.61%, ranking 856 out of 3,865; and since inception, it has returned 245.57% [2]

Core Insights - The medical device sector experienced a slight increase of 0.34% on October 16, with Yingke Medical leading the gains [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Medical Device Sector Performance - Yingke Medical (300677) closed at 45.50, up 6.28% with a trading volume of 410,600 shares [1] - Haitai New Light (688677) closed at 54.75, up 4.74% with a trading volume of 36,000 shares [1] - Spring Medical (688236) closed at 24.49, up 4.57% with a trading volume of 33,900 shares [1] - Other notable performers include Baijun Medical (688198) up 4.48%, and Kangzhong Medical (688607) up 4.43% [1] Fund Flow Analysis - The medical device sector saw a net inflow of 262 million yuan from institutional investors, while retail investors experienced a net outflow of 339 million yuan [2] - Major stocks like Yingke Medical had a net inflow of 172 million yuan from institutional investors, indicating strong institutional interest [3] - Conversely, stocks like Wuzhou Medical (301234) faced a significant decline of 7.08% with a trading volume of 34,500 shares [2]

Group 1 - The core point of the news is that Yingke Medical's stock price increased by 5.05% to 44.97 CNY per share, with a trading volume of 8.11 billion CNY and a turnover rate of 4.04%, resulting in a total market capitalization of 294.46 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - Among the top ten circulating shareholders of Yingke Medical, E Fund's Chuangye ETF (159915) reduced its holdings by 272,900 shares in the second quarter, now holding 10.6244 million shares, which accounts for 2.26% of circulating shares [2] - The E Fund Chuangye ETF (159915) was established on September 20, 2011, with a latest scale of 85.537 billion CNY, achieving a year-to-date return of 43.03% and a one-year return of 46.72% [2] Group 3 - The fund managers of E Fund Chuangye ETF are Cheng Xi and Liu Shurong, with Cheng having a tenure of 9 years and 165 days and a total fund size of 195.312 billion CNY, while Liu has a tenure of 8 years and 93 days with a fund size of 112.299 billion CNY [3]

Group 1 - The company, Yingke Medical, announced that its fourth board meeting will be held on October 15, 2025, combining in-person and communication methods [1] - The meeting will review the proposal regarding the grant of reserved shares under the 2025 restricted stock incentive plan to incentive objects [1]

英科医疗科技股份有限公司 董事会薪酬与考核委员会关于 2025 年限制性股票激励计划 预留授予激励对象名单（预留授予日）的核查意见 英科医疗科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员会 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理 办法》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、 《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》和《英科 医疗科技股份有限公司章程》（以下简称"《公司章程》"）等有关规定，对公司 2025 年限制性股票激励计划（以下简称"本激励计划"）预留授予激励对象名单 （预留授予日）进行审核，并发表核查意见如下： 一、本激励计划预留授予的激励对象均不存在《管理办法》及《上市规则》 规定的不得成为激励对象的情形： （一）最近 12 个月内被证券交易所认定为不适当人选； 二、本激励计划预留授予的激励对象为公司（含分、子公司，下同）董事及 高级管理人员。激励对象不包括公司独立董事、外籍员工、单独或合计持有公司 5%以上股份的股 ...